期刊文献+

HER-2阴性LuminalB型乳腺癌的临床病理特征研究 被引量:1

Research on the Pathological and Clinical Features of HER- 2- negative- Luminal- B Type Breast Cancer
下载PDF
导出
摘要 目的探讨HER-2阴性Luminal B型乳腺癌3种亚型的临床病理特征的差别并与Luminal A型乳腺癌进行比较,探索能否将3种亚型中的一部分乳腺癌独立出来重新归为Luminal A型乳腺癌。方法回顾性分析126例HER-2阴性Luminal B型乳腺癌患者,并将其分为3组:组1为PR<20%且Ki-67<14%,组2为Ki-67≥14%且PR≥20%,组3为PR<20%且Ki-67≥14%,分析各组间临床病理资料的差异,并分别与Luminal A型乳腺癌进行比较。结果 HER-2阴性Luminal B型乳腺癌的3个亚组中,肿块直径组1与组3比较差异有统计学意义(P=0.040),组1与组2、组2与组3间比较差异无统计学意义(P>0.05);腋窝淋巴结转移组1与组2比较差异有统计学意义(P<0.05),组1与组3、组2与组3间差异无统计学意义(P>0.05);3个亚组在组织学分级及绝经状态方面差异互无统计学意义(P>0.05);发病年龄组1与组2、组1与组3差异有统计学意义(P<0.05),组2与组3差异无统计学意义(P>0.05);组1与组2在组织类型方面差异有统计学意义(P<0.05),组1与组3、组2与组3在组织类型方面差异无统计学意义(P>0.05);将Luminal A型乳腺癌与组1、组2、组3比较,Luminal A型乳腺癌与组1的临床病理特征差异无统计学意义,而与组2、组3差异有统计学意义。结论 Luminal B型中的HER-2阴性Luminal B型乳腺癌可分为3个亚组,它们在临床病理方面存在着一定的差异,且组1与Luminal A型乳腺癌临床病理特征差异无统计学意义,或许能将组1重新归为Luminal A型乳腺癌,但需进一步前瞻性研究来证实。 Objective To explore the pathological and clinical features difference of patients with HER - 2 - negative - Luminal - B type breast cancer. Methods Totally 126 patients with HER - 2 - negative - Luminal - B type breast cancer patients were divided into 3 groups, and were analyzed retrospectively. In the first group, PR was lower than 20% and Ki - 67 was lower than 14%. In the second group, PR was higher or equal to 20% and Ki -67 was higher than or equal to 14%. In the third group, PR was lower than 20% and Ki - 67 was higher than or equal to 14%. We collected clinical and pathology data, and analyzed difference of HER - negative - Luminal - B type breast cancer, and then compared with Luminal - A Type. Results Among the three subtypes of HER - 2 - negative - Luminal - B type breast cancer, the difference of tumer size brtween group 1 and group 3 was significant, the other was not significant. Compared with group 2, the group 1 was statistically significant of lymphatic metastasis(P 〈 0. 05 ) , the diffrence of group 1 with group 3 and guoup 2 with group 3 was not significant(P 〉 0. 05) , the pathological grade was not statistically significant among the 3 groups(P 〉 0. 05) , the difference of menopause among three groups was not significant(P 〉 0.05). Compared with group 2, the group 1 was statistically signifi- cant of pathological pattern( P 〈 0.05 ) , the difference among groupl with group 2 ang group 2 with group3 was not significant( P 〉 0.05 ), the difference of age between group 1 and group 2, while between group 1 ang group 3 was statistically significant (P 〈 O. 05) , among group 2 with group 3 was not significant(P 〉 0.05 ). The difference of pathological and clinical features between Luminal - A type breast cancer an group 1 were not significant, but comapred with group 2 and group 3, the Luminal - A type breast cancer was statistically signif- icant of pathological and clinical features. Conclusion According to PR and Ki - 67, current HER - 2 - negative - Luminal - B type breast cancer can be divided into three different subtypes, which has different pathological and clinical features and the difference of patho- logical and clinical features between Luminal - A type breast cancer an group 1 were not significant that may redefined the group 1 as Lu- minal- A type breast cancer,but needs further study to demonstrate it.
作者 刘虔 孙圣荣
出处 《医学研究杂志》 2016年第11期169-173,共5页 Journal of Medical Research
关键词 HER-2阴性LuminalB 乳腺癌 临床病理特征 HER - 2 - negative - Luminal - B type Breast cancer Pathological and clinical features
  • 相关文献

参考文献2

二级参考文献39

  • 1Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Int J Cancer, 1983, 31 ( 1 ) : 13-20.
  • 2Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer [J]. Exp Ther Med, 2010,1(5) :747-754.
  • 3Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis [J]. Int J Cancer, 1997, 74 (4) :433437.
  • 4Locker AP, Birrell K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival[J]. Eur J Surg Oncol, 1992, 18(3) :224-229.
  • 5Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797) :747-752.
  • 6Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [J]. Proc Natl Acad Sci USA, 2003,100(14) :8418-8423.
  • 7Railo M, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 iinmunolabelling in primary operable breast cancer [J] . Br J Cancer, 1993, 68 (3) :579-583.
  • 8Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [J]. J Natl Cancer Inst, 2009, 101 (10) : 736-750.
  • 9Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the SI. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8) :1736- 1747.
  • 10Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole [J]. J Clin Oncol, 2008, 26 (34) :5569-5575.

共引文献59

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部